Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRG2 | P18507 | 2/20 | 0.37 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.37 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.37 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.37 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.37 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.37 |
| ▸ | NLRP3 | Q96P20 | 5/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | PDE5A | O76074 | 1/20 | 0.32 |
| ▸ | F10 | P00742 | 1/20 | 0.31 |
| ▸ | CASK | O14936 | 1/20 | 0.31 |
| ▸ | ACACB | O00763 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30842213 | 0.79 | KCNH2 (0.44) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL20741495 | 0.79 | KCNH2 (0.44) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL3862390 | 0.73 | ALDH1A1 (0.41) | KMT2AMAPK1CASK | |
| SCHEMBL20762209 | 0.71 | LMNA (0.34) | NLRP3 | |
| SCHEMBL21566299 | 0.69 | KCNH2 (0.36) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL26862594 | 0.67 | NLRP3 (0.59) | NLRP3 | |
| SCHEMBL20969995 | 0.67 | TLR8 (0.35) | — | |
| SCHEMBL3872563 | 0.66 | ALDH1A1 (0.39) | KMT2AMAPK1CASK | |
| SCHEMBL21550561 | 0.66 | KCNH2 (0.39) | NLRP3KCNH2KMT2AMAPK1ACACB | |
| SCHEMBL20475982 | 0.65 | NLRP3 (0.54) | NLRP3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200157096-A1 | NLRP3 MODULATORS | INNATE TUMOR IMMUNITY INC (US) | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200157096-A1 | NLRP3 MODULATORS | NLRP3, NLRP1, NOD1 | GABRG2 1034/4885GABRB3 1588/4885GABRA5 1319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.